Update information
April 2023 Recommendation 1.3 was updated and replaced by NICE highly specialised technologies guidance on onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy.
ISBN: 978-1-4731-5138-3
April 2023 Recommendation 1.3 was updated and replaced by NICE highly specialised technologies guidance on onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy.
ISBN: 978-1-4731-5138-3